prikaz prve stranice dokumenta TIGIT therapy for cancer treatment – TIGITtherapy – ERC
  Preuzmi
PDF 412.83 KB
Ostalo - Popularni rad
TIGIT therapy for cancer treatment – TIGITtherapy – ERC
Impact, 2018 (2018), 10; 51-53. https://doi.org/10.21820/23987073.2018.10.51
Mandelboim, Ofer; Jonjić, Stipan; Kučan Brlić, Paola; Tsukerman, Pinchas

Citirajte ovaj rad

Mandelboim, O., Jonjić, S., Kučan Brlić, P. i Tsukerman, P. (2018). TIGIT therapy for cancer treatment – TIGITtherapy – ERC. Impact, 2018. (10), 51-53. doi: 10.21820/23987073.2018.10.51

Mandelboim, Ofer, et al. "TIGIT therapy for cancer treatment – TIGITtherapy – ERC." Impact, vol. 2018, br. 10, 2018, str. 51-53. https://doi.org/10.21820/23987073.2018.10.51

Mandelboim, Ofer, Stipan Jonjić, Paola Kučan Brlić i Pinchas Tsukerman. "TIGIT therapy for cancer treatment – TIGITtherapy – ERC." Impact 2018, br. 10 (2018): 51-53. https://doi.org/10.21820/23987073.2018.10.51

Mandelboim, O., et al. (2018) 'TIGIT therapy for cancer treatment – TIGITtherapy – ERC', Impact, 2018(10), str. 51-53. doi: 10.21820/23987073.2018.10.51

Mandelboim O, Jonjić S, Kučan Brlić P, Tsukerman P. TIGIT therapy for cancer treatment – TIGITtherapy – ERC. Impact [Internet]. 21.12.2018. [pristupljeno 14.11.2024.];2018(10):51-53. doi: 10.21820/23987073.2018.10.51

O. Mandelboim, S. Jonjić, P. Kučan Brlić i P. Tsukerman, "TIGIT therapy for cancer treatment – TIGITtherapy – ERC", Impact, vol. 2018, br. 10, str. 51-53, Prosinac 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:389585. [Citirano: 14.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:389585
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)TIGIT therapy for cancer treatment – TIGITtherapy – ERC
AutorOfer Mandelboim
AutorStipan Jonjić
AutorPaola Kučan Brlić
AutorPinchas Tsukerman
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed highly specific blocking antibodies, that block TIGIT at pM affinity and restore effector function of NK and T cells.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeOstalo - Popularni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaImpact
Brojčani podacivol. 2018, br. 10, str. 51-53
p-ISSN2398-7073
DOIhttps://doi.org/10.21820/23987073.2018.10.51
URN:NBNurn:nbn:hr:184:389585
Datum objave publikacije2018-12-21
ProjektŠifra: 721317
Naziv (engleski): TIGIT therapy for cancer treatment
Kratica: TIGITtherapy
Pravna nadležnost: eu
Financijer: EC
Linija financiranja: H2020
URL dokumentahttps://www.ingentaconnect.com/content/10.21820/23987073.2018.10.51
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-10-19 07:52:32